Mesenchymal stem cells (MSCs) are multipotent stromal cells that are able to differentiate into a number of tissues such as bone, fat, cartilage, and muscle. They can be isolated from a number of sources, and because of their differentiation and immunomodulatory properties, they have relevant and significant clinical therapeutic applications. MSCs are currently being used to treat a number of clinical conditions, as well as being tested in preclinical and clinical trials around the world due to their tissue regenerative properties.
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In this special issue, we have a number of primary research articles examining the potential clinical application or preclinical studies of MSCs or their derivatives. The topics that are covered include the isolation from different sources, derivation, differentiation, quality control, and transplantation studies involving MSCs. We also have a number of review articles relating to the abovementioned aspects of MSCs. This special issue summarizes the most recent developments in the field in the following areas: M. Zhang et al. investigated the effect of donor age on the properties of human eyelid adipose-derived stem cells (HEASCs). HEASCs from a number of age groups were evaluated and quantified for their proliferative capacity, colony-forming ability, surface markers, differentiation ability, secreted proteins, and wound healing function.
A. Mizukam and K. Swiech reviewed the current MSC manufacturing platforms with special attention regarding the use of bioreactors for the production of GMP compliant clinically relevant cell numbers. They also addressed first commercial MSC-based products.
M. M. Viganò et al. provided a comprehensive article on the strategies and the results of validation studies applied to GMP quality control methods for the clinical use of mesenchymal stromal cells (MSC). They provide a useful tool to face the hurdles in the application of the rules regulating the quality control of cell therapy medicinal products such as MSC.
K. Ye et al. investigate the use of endometrial regenerative cells (ERCs) in aorta allografts in mouse models and found that overexpression of B7-H1, also known as programmed cell death-1 ligand (PD-L1), stimulated by IFN-γ is required for ERCs to prevent the transplant vasculopathy.
W. Zhun et al. investigated the efficiency of the allograft bone marrow stem cells (BMSCs) with Dkk-1 interference in preventing the progress of the rat model for hip disorder glucocorticoid-induced osteonecrosis of the femoral head. They showed that lentivirus-meditated Dkk-1 RNAi resulted in the promotion of osteogenesis and inhibition of adipogenesis. The progression of the disease was prevented; however, the effects were not significantly superior to treatment with nongenetically modified or normal BMSCs.
K. Ye et al. demonstrated that B7-H1 expression on endometrial regenerative cells (ERCs) was upregulated by IFN-γ in a dose-dependent manner, and it was required for ERCs to inhibit the proliferation of peripheral blood mononuclear cells (PBMCs) in vitro. This study provides a theoretical basis for the future clinical use of human ERCs.
M. Zayed et al. investigated the in vivo potential of synovial fluid-derived mesenchymal stem cells and bone marrow-derived MSCs in articular cartilage repair. They performed xenogenic implantation of equine MSCs in a rat osteochondral defect model and evaluated articular cartilage healing.
B. Zhang et al. observed significantly higher improvement in cartilage neogenesis and recovery using canine umbilical cord mesenchymal stem cells (UC-MSCs) on treatment of knee osteoarthritis in dogs. The joint fluid and the inflammatory response decreased. Moreover, improved recovery in the neogenetic cartilage, damaged skin fascia, and muscle tissue around the joints was more significant in the treated group.
